Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

HP-228 reduces obesity and insulin resistance in animal models

April 23, 1999

Avandia approved in Mexico, approval recommended in U.S.

April 23, 1999

Novel cytotoxic agent from Nippon Steel with potential in inflammation and osteoporosis

April 22, 1999

Abarelix depot is safe and effective in patients with endometriosis

April 22, 1999

Novavax estrogen cream completes phase II trial

April 22, 1999

Hemosol's oxygen carrier cleared for phase III trials in Canada

April 21, 1999

Novel microbial metabolites activate glucokinase activity

April 21, 1999

Vivus receives patent protection for female sexual dysfunction therapy

April 21, 1999

CardioRex versus probucol in atherosclerosis model

April 19, 1999

Hericenal C: new enzyme inhibitor for diabetes mellitus

April 19, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...